PT3744835T - Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas - Google Patents

Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas

Info

Publication number
PT3744835T
PT3744835T PT201837408T PT20183740T PT3744835T PT 3744835 T PT3744835 T PT 3744835T PT 201837408 T PT201837408 T PT 201837408T PT 20183740 T PT20183740 T PT 20183740T PT 3744835 T PT3744835 T PT 3744835T
Authority
PT
Portugal
Prior art keywords
methods
fusion proteins
dna modifying
modifying fusion
dna
Prior art date
Application number
PT201837408T
Other languages
English (en)
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of PT3744835T publication Critical patent/PT3744835T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT201837408T 2012-05-29 2013-05-29 Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas PT3744835T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261652711P 2012-05-29 2012-05-29
US13/838,520 US9890364B2 (en) 2012-05-29 2013-03-15 TAL-Tet1 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
PT3744835T true PT3744835T (pt) 2024-05-31

Family

ID=49670524

Family Applications (1)

Application Number Title Priority Date Filing Date
PT201837408T PT3744835T (pt) 2012-05-29 2013-05-29 Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas

Country Status (6)

Country Link
US (3) US9890364B2 (pt)
EP (4) EP2879693B1 (pt)
DK (1) DK3744835T5 (pt)
ES (1) ES2979326T3 (pt)
PT (1) PT3744835T (pt)
WO (1) WO2013181228A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012674A1 (en) 2011-07-15 2013-01-24 The General Hospital Corporation Methods of transcription activator like effector assembly
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP2906602B1 (en) 2012-10-12 2019-01-16 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
US10704060B2 (en) 2013-06-05 2020-07-07 Duke University RNA-guided gene editing and gene regulation
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
WO2015191911A2 (en) * 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
CA2973878A1 (en) * 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
CN107690480B (zh) 2015-04-24 2022-03-22 爱迪塔斯医药公司 Cas9分子/指导rna分子复合物的评价
EP3362571A4 (en) 2015-10-13 2019-07-10 Duke University GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066796A2 (en) * 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US11512311B2 (en) 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
WO2017189542A1 (en) * 2016-04-26 2017-11-02 University Of Georgia Research Foundation, Inc. Plants having reduced methylation of cytosine nucleotides and methods of use
BR112019001887A2 (pt) 2016-08-02 2019-07-09 Editas Medicine Inc composições e métodos para o tratamento de doença associada a cep290
AU2017327384B2 (en) * 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
AU2017341926B2 (en) 2016-10-14 2022-06-30 The General Hospital Corporation Epigenetically regulated site-specific nucleases
EP3532638A4 (en) 2016-10-31 2020-07-29 University of Massachusetts TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
AU2018213044B2 (en) * 2017-01-26 2024-08-01 The Regents Of The University Of California Targeted gene demethylation in plants
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
SG11202008956XA (en) 2018-03-14 2020-10-29 Editas Medicine Inc Systems and methods for the treatment of hemoglobinopathies
CN111700034B (zh) * 2020-05-22 2021-12-14 中国人民解放军空军军医大学 一种基于中枢神经系统髓鞘功能改变的精神分裂症动物模型的构建方法和应用
WO2024073043A1 (en) * 2022-09-30 2024-04-04 Illumina, Inc. Methods of using cpg binding proteins in mapping modified cytosine nucleotides

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6900306B2 (en) 2001-08-01 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of CoREST expression
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2131630A1 (en) 1992-03-10 1993-09-30 Yury E. Khudyakov Exchangeable template reaction
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
ATE407205T1 (de) 1994-08-20 2008-09-15 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
GB9618544D0 (en) 1996-09-05 1996-10-16 Brax Genomics Ltd Characterising DNA
DE19812103A1 (de) 1998-03-19 1999-09-23 Bernauer Annette Verfahren zur Synthese von Nucleinsäuremolekülen
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
DE19925862A1 (de) 1999-06-07 2000-12-14 Diavir Gmbh Verfahren zur Synthese von DNA-Fragmenten
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US20020164575A1 (en) 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification
ATE355368T1 (de) 2000-01-24 2006-03-15 Gendaq Ltd Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne
US20020064802A1 (en) 2000-04-28 2002-05-30 Eva Raschke Methods for binding an exogenous molecule to cellular chromatin
EP1276860B1 (en) 2000-04-28 2007-09-26 Sangamo Biosciences Inc. Databases of regulatory sequences; methods of making and using same
AU2001253914B2 (en) 2000-04-28 2006-06-08 Sangamo Therapeutics, Inc. Targeted modification of chromatin structure
US6511808B2 (en) 2000-04-28 2003-01-28 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
US7029847B2 (en) 2000-05-16 2006-04-18 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
JP2002262870A (ja) 2000-11-09 2002-09-17 Nara Institute Of Science & Technology 固相において二本鎖ｄｎａ分子を順次連結する方法およびその装置
AU2002225187A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2003304086A1 (en) 2002-10-23 2004-11-26 Massachussetts Institute Of Technlogy Context sensitive parallel optimization of zinc finger dna binding domains
AU2005322312B2 (en) 2004-12-16 2011-05-26 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
ATE547514T1 (de) 2005-10-28 2012-03-15 Univ North Carolina Protein-demethylasen mit einer jmjc-domäne
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
DE602007005634D1 (de) 2006-05-25 2010-05-12 Sangamo Biosciences Inc Variante foki-spaltungshälften-domänen
WO2009042753A1 (en) 2007-09-28 2009-04-02 Two Blades Foundation Bs3 resistance gene and methods of use
AU2009243187C1 (en) 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
ES2869955T3 (es) 2008-04-30 2021-10-26 Sanbio Inc Células de regeneración neural con alteraciones en la metilación del ADN
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
BRPI0921909A2 (pt) 2008-11-10 2017-06-13 Two Blades Found métodos para fabricar um promotor indutível por patógeno, e um gene r, para intensificar a resistência de uma planta, e para identificar uma caixa upa, promotor indutível por patógeno, cassete de expressão, molécula de ácido nucléico, planta transformada, semente da planta transformada, célula hospedeira.
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
EP2424877A4 (en) 2009-04-28 2013-01-02 Harvard College SUPERCHARGED PROTEINS FOR CELL PENETRATION
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
CA2770312A1 (en) 2009-08-11 2011-02-17 Sangamo Biosciences, Inc. Organisms homozygous for targeted modification
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
JP2013513389A (ja) 2009-12-10 2013-04-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｔａｌエフェクターに媒介されるｄｎａ修飾
DK2534173T3 (da) 2010-02-08 2019-10-14 Sangamo Therapeutics Inc Manipulerede spaltnings-halvdomæner
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
WO2012138939A1 (en) 2011-04-05 2012-10-11 Philippe Duchateau New tale-protein scaffolds and uses thereof
WO2013012674A1 (en) 2011-07-15 2013-01-24 The General Hospital Corporation Methods of transcription activator like effector assembly
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
EP2906602B1 (en) 2012-10-12 2019-01-16 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
EP3467125B1 (en) 2013-03-15 2023-08-30 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing

Also Published As

Publication number Publication date
EP3747999A1 (en) 2020-12-09
ES2979326T3 (es) 2024-09-25
EP4368249A3 (en) 2024-07-24
DK3744835T3 (da) 2024-05-06
US9890364B2 (en) 2018-02-13
DK3744835T5 (da) 2024-08-26
US20130323220A1 (en) 2013-12-05
EP3744835B1 (en) 2024-01-31
EP3744835A1 (en) 2020-12-02
US10894950B2 (en) 2021-01-19
EP2879693A4 (en) 2016-04-13
EP2879693B1 (en) 2020-07-08
EP3747999B1 (en) 2021-09-15
US20210155907A1 (en) 2021-05-27
EP4368249A2 (en) 2024-05-15
US20180187168A1 (en) 2018-07-05
WO2013181228A1 (en) 2013-12-05
EP2879693A1 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
EP2879693A4 (en) DNA-MODIFYING FUSION PROTEINS AND METHODS OF USE THEREOF
HK1251589A1 (zh) 靶向/免疫調節性融合蛋白及其製造方法
HK1209439A1 (en) Interleukin-10 fusion proteins and uses thereof -10
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
EP2928924A4 (en) HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
HK1205195A1 (en) Cd47 antibodies and methods of use thereof cd47
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
PT2925782T (pt) Anticorpos anti-cd47 e métodos de utilização destes
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2711376A4 (en) FGFR-FC FUSION PROTEIN AND USE THEREOF
HK1203161A1 (en) Peptides and methods of using same
HK1209432A1 (en) Anti-jagged antibodies and methods of use
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
PT2804875T (pt) Ferramentas e métodos para expressão de proteínas de membrana
ZA201504817B (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use
AU2012901619A0 (en) Fusion Proteins and Use Thereof